Negative effect of treatment with mGluR5 negative allosteric modulator AFQ056 on blood biomarkers in young individuals with Fragile X syndrome.
Saved in:
| Title: | Negative effect of treatment with mGluR5 negative allosteric modulator AFQ056 on blood biomarkers in young individuals with Fragile X syndrome. |
|---|---|
| Authors: | Protic D; Faculty of Medicine, Department of Pharmacology, Clinical Pharmacology, and Toxicology, University of Belgrade, Belgrade, Serbia.; Fragile X Clinic, Special Hospital for Cerebral Palsy and Developmental Neurology, Belgrade, Serbia., Breeze E; Department of Medical Microbiology and Immunology, School of Medicine, University of California Davis, Davis, CA, USA.; MIND Institute, University of California Davis, Sacramento, CA, USA., Mendoza G; Department of Biochemistry and Molecular Medicine, School of Medicine, University of California Davis, Sacramento, CA, USA., Zafarullah M; Department of Biochemistry and Molecular Medicine, School of Medicine, University of California Davis, Sacramento, CA, USA., Abbeduto L; MIND Institute, University of California Davis, Sacramento, CA, USA.; Department of Psychiatry and Behavioral Sciences, University of California Davis, Sacramento, CA, USA., Hagerman R; MIND Institute, University of California Davis, Sacramento, CA, USA.; Department of Pediatrics, University of California Davis, Sacramento, CA, USA., Coffey C; Department of Biostatistics, University of Iowa, Iowa City, IA, USA., Cudkowicz M; Department of Neurology, Massachusetts General Hospital, Boston, MA, USA., Durbin-Johnson B; Division of Biostatistics, Department of Public Health Sciences, University of California, Davis, CA, USA., Ashwood P; Department of Medical Microbiology and Immunology, School of Medicine, University of California Davis, Davis, CA, USA., Berry-Kravis E; Department of Pediatrics, Neurological Sciences, Anatomy, and Cell Biology, Rush University Medical Center, Chicago, IL, USA., Erickson CA; Cincinnati Hospital and Medical Center, Cincinnati, OH, USA., Filipink R; Children's Hospital of Pittsburgh, Pittsburgh, PA, USA., Gropman A; Children's National Medical Center, Washington, DC, USA., Lehwald L; Nationwide Children's Hospital, Columbus, OH, USA., Maxwell-Horn A; Vanderbilt University Medical Center, Nashville, TN, USA., Morris S; Washington University Medical Center, Saint Louis Children's Hospital, St. Louis, MO, USA., Bennett AP; Children's Hospital of Philadelphia, Philadelphia, PA, USA., Prock L; Boston Children's Hospital, Boston, MA, USA., Talboy A; Emory University Medical Center, Atlanta, GA, USA., Tartaglia N; Children's Hospital of Colorado, Denver, CO, USA., Veenstra-VanderWeele J; Center for Autism and the Developing Brain, New York-Presbyterian, New York, NY, USA.; Department of Psychiatry, Columbia University, New York, NY, USA.; New York State Psychiatric Institute, New York, NY, USA., Tassone F; MIND Institute, University of California Davis, Sacramento, CA, USA.; Department of Biochemistry and Molecular Medicine, School of Medicine, University of California Davis, Sacramento, CA, USA. |
| Source: | SAGE open medicine [SAGE Open Med] 2024 Sep 29; Vol. 12, pp. 20503121241282401. Date of Electronic Publication: 2024 Sep 29 (Print Publication: 2024). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: SAGE Publications Country of Publication: England NLM ID: 101624744 Publication Model: eCollection Cited Medium: Print ISSN: 2050-3121 (Print) Linking ISSN: 20503121 NLM ISO Abbreviation: SAGE Open Med Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
